Kidney Cancer Archives - Page 61 of 62 - Renal and Urology News

Kidney Cancer

Predicting RCC Outcomes: An Update

Despite current therapies, renal cell carcinoma (RCC) is often lethal. Many factors influence outcomes, including stage, grade, subtype, necrosis, and molecular attributes. Prognosis can be difficult to determine. Comprehensive staging strategies that incorporate multiple patients and tumor factors are necessary to predict survival accurately and optimize research strategies. Recently designed algorithms allow for convenient and up-to-date estimates of outcome in this rapidly evolving field.

Post-Cryo Salvage Difficult

Post-Cryo Salvage Difficult

ANAHEIM, Calif.—Salvage surgery may be quite problematic for patients who experience recurrence of renal cell carcinoma following primary thermal ablation, researchers reported.

Another Renal Cancer Drug Reaches Phase II

Rexahn Pharmaceuticals, Inc., of Rockville, Md., has announced that it has received approval to begin a phase II study for its lead oncology compound, Archexin (formerly known as RX-0201), in patients with advanced renal cell carcinoma.

Stereotactic Radiosurgery Beneficial

SAN DIEGO—Stereotactic radiosurgery produces early and durable responses in renal cell carcinoma (RCC) patients with either previously untreated spinal metastases or spinal metastases that have recurred after prior radiotherapy, researchers announced here at the 2007 Annual Meeting of the American Academy of Orthopedic Surgeons.

FDA Strengthens ESA Safety Information

The FDA issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs). The drugs affected by the safety update are darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit).

Next post in FDA News